Abbott Laboratories Inc. landed U.S. FDA clearance for its Freestyle Libre 3 integrated continuous glucose monitoring system (CGM)’s reader device a bit earlier than expected. With the regulatory ...

ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

"Sensor-based glucose monitoring has transformed diabetes care," said Akshay Jain, M.D., a nationally recognized endocrinologist based in Surrey, British Columbia. "These intuitive tools, like the ...

Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that a number of them may be ...

Medical device giant Abbott announced on Sunday that it is recalling approximately 3 million glucose monitoring sensors after discovering they could give dangerously inaccurate low blood sugar ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Abbott issued a medical device correction for some ...

ABBOTT PARK, Ill., July 24, 2024 – Abbott has initiated a voluntary medical device correction for a small number of FreeStyle Libre® 3 sensors distributed in the United States during the first half of ...

Abbott Laboratories ABT recently made its FreeStyle Libre 3 Plus sensor available to Canadians living with diabetes. This latest generation glucose monitoring device features the world's smallest ...

Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...

Coverage means more Canadians with diabetes can access Abbott's sensor-based glucose technology, giving them actionable insights to manage their condition confidently, i "Sensor-based glucose ...